Endothelin-1 may be key in mediating ischemia-reperfusion injury in patients with diabetics and use of endothelin receptor antagonists might be a novel approach to improving resistance of the diabetic heart to cardioplegic arrest and reperfusion.
These suggestions are from a pair of Canadian studies by doctors from Toronto General Hospital, University of Toronto, Toronto, Ontario, and Foothills Hospital, University of Calgary, Calgary, Alberta. The two studies were done against a backdrop of accumulating evidence that diabetic patients face increased risk of ischemic events and low output syndrome, and may mount an inordinate response to ischemia and reperfusion. Hyperglycemia is a potent stimulus for endothelin-1 production. Thus, increased production, action, or both, of endothelin-1 in these patients could prove to be an important mediator of endothelial dysfunction.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!